^
    22h
    MCC-20963: Fedratinib in Myelodysplastic /Myeloproliferative Neoplasms (MDS/MPNs) and Chronic Neutrophilic Leukemia (CNL) (clinicaltrials.gov)
    P2, N=25, Completed, H. Lee Moffitt Cancer Center and Research Institute | Active, not recruiting --> Completed
    Trial completion
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    Inrebic (fedratinib)
    2d
    Assessment of Tfh Cells and Related Molecules in CML-CP Patients With Different Molecular Responses. (PubMed, Int J Lab Hematol)
    Pre-MMR CML-CP is accompanied by aberrant Tfh cell differentiation and an immunosuppressive immune signature linked to suboptimal molecular responses. Targeting immune checkpoints or modulating Tfh cell homeostasis may help improve therapeutic outcomes in CML-CP.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-1 (Programmed cell death 1) • BCL6 (B-cell CLL/lymphoma 6) • PD-L2 (Programmed Cell Death 1 Ligand 2) • CD4 (CD4 Molecule) • PRDM1 (PR/SET Domain 1) • CXCR5 (C-X-C Motif Chemokine Receptor 5)
    3d
    PONAT-14-25: An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivalence study comparing Ponatinib Tablets 15 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Iclusig (Ponatinib hydrochloride) tablets 15 mg, Produced by: Patheon Inc. Mississauga, Canada or Takeda Ireland Limited Bray, Ireland, Imported and registered by: Pint Pharma Medical-Hospital and Pharmaceutical Products Ltd. Nelson Pontes Street, 125, Block 03, Jardim Margarida Zip Code 06739-024, Vargem Grande Paulista SP CNPJ No. 21,896,000/0001-91, in healthy adult, human subjects under fasting condition. (2025-524311-37-00)
    P1, N=56, Recruiting, Sun Pharmaceutical Industries Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Iclusig (ponatinib)
    3d
    Impact of Somatic Mutations on Treatment Response and Resistance in Chronic Myeloid Leukemia. (PubMed, Int J Lab Hematol)
    In this Indian CML cohort, somatic mutations were prevalent in TKI-resistant disease, linked to advanced phase and clonal complexity, and demonstrated a non-significant trend toward lower early MMR at diagnosis, highlighting the importance of genomic testing in this context.
    Journal
    |
    ABL1 (ABL proto-oncogene 1) • ASXL1 (ASXL Transcriptional Regulator 1)
    |
    ASXL1 mutation
    4d
    Integrated Cytogenetic and FISH Profiling Reveals inv(16) Dominance and Cryptic 11q23 Lesions in AML and ALL: Clinical Significance from a Referral Cohort. (PubMed, J Assoc Genet Technol)
    Conventional karyotyping and targeted FISH probes were employed to identify recurrent and rare chromosomal abnormalities, with a special emphasis on inv(16) (p13.1q22), MLL rearrangements, and complex karyotypes. Our findings highlight the indispensable role of integrating cytogenetics and FISH in routine diagnostic workflows, especially in cases with cryptic rearrangements or subclonal abnormalities, thereby underscoring their clinical and prognostic significance.
    Journal
    |
    KMT2A (Lysine Methyltransferase 2A)
    |
    MLL rearrangement
    4d
    Sigma-1 Receptor antagonism potentiates siramesine-induced apoptosis and altered autophagic signaling in human leukemia cells. (PubMed, Biomed Pharmacother)
    Co-treatment with BD-1047 further enhanced Siramesine-induced cell death, apoptosis, and alterations in autophagic signaling. These findings demonstrate that S1R inhibition sensitizes leukemia cells to S2R-mediated cytotoxicity, supporting the therapeutic potential of combined sigma receptor targeting and warranting further investigation of Siramesine-based metronomic therapy in leukemia.
    Journal
    |
    SQSTM1 (Sequestosome 1) • BAX (BCL2-associated X protein) • CASP8 (Caspase 8)
    5d
    The evolving landscape of regulatory T cells in leukemia: from mechanisms to advanced immunotherapeutic strategies. (PubMed, Front Immunol)
    A significant portion of this review examines the evolving therapeutic landscape, scrutinizing Treg-depleting antibodies (e.g., mogamulizumab, RG6292), immunomodulatory small molecules (venetoclax, hypomethylating agents, TKIs), and the challenges Tregs pose to cellular therapies. Finally, we discuss novel strategies to circumvent Treg-mediated resistance, offering a perspective on restoring anti-leukemic immunity.
    Review • Journal • IO biomarker
    |
    CD73 (5'-Nucleotidase Ecto) • CCR4 (C-C Motif Chemokine Receptor 4) • IL2RA (Interleukin 2 receptor, alpha) • CD4 (CD4 Molecule) • CCL2 (Chemokine (C-C motif) ligand 2) • FOXP3 (Forkhead Box P3) • CCL22 (C-C Motif Chemokine Ligand 22) • ENTPD1 (Ectonucleoside Triphosphate Diphosphohydrolase 1)
    |
    IL2RA expression
    |
    Venclexta (venetoclax) • Poteligeo (mogamulizumab-kpkc) • vopikitug (RG6292)
    5d
    Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia (clinicaltrials.gov)
    P2, N=20, Completed, M.D. Anderson Cancer Center | Active, not recruiting --> Completed | Trial completion date: Nov 2026 --> Jun 2026 | Trial primary completion date: Nov 2026 --> Jun 2026
    Trial completion • Trial completion date • Trial primary completion date
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • BCL2 (B-cell CLL/lymphoma 2)
    |
    Venclexta (venetoclax) • Iclusig (ponatinib) • decitabine
    6d
    Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases (clinicaltrials.gov)
    P2, N=20, Recruiting, University of Florida | Trial completion date: May 2027 --> May 2028 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3)
    |
    FLT3 mutation • CBL mutation
    6d
    Concurrent Chronic Myeloid Leukemia and Metastatic Renal Cell Carcinoma in a 61-year-old Female: Successful Treatment with Low-Dose Immunotherapy and Combination Targeted Therapy. (PubMed, J Kidney Cancer VHL)
    The patient had a history of CML treated with imatinib for 4 years, with loss of complete hematological response for 3 months before being diagnosed with RCC and lung metastases. Due to a T315I mutation in the BCR-ABL1 gene, the treatment regimen included a novel combination of Axitinib, Dasatinib, and low-dose nivolumab. The patient showed a remarkable therapeutic response with a complete metabolic response accompanied by a highly significant reduction in the size of the tumor and complete resolution of the metastatic lung lesions, as well as a major molecular response in terms of CML disease control.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase)
    |
    ABL1 T315I
    |
    Opdivo (nivolumab) • dasatinib • imatinib • axitinib